Lv15
88 积分 2025-08-26 加入
WS19.05 A Phase II trial (CLAIRAFLY) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase 1 inhibitor BI 1291583 in adults with bronchiectasis due to cystic fibrosis
1小时前
求助中
PRAGMA-CF. A Quantitative Structural Lung Disease Computed Tomography Outcome in Young Children with Cystic Fibrosis
16小时前
已完结
Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older – The RECOVER Trial
16小时前
已完结
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
22小时前
已完结
Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program
2天前
已完结
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
4天前
已完结
IL-33, inflammation and mucus in COPD: the final FRONTIER?
4天前
已完结
A Compound Heterozygous Cathepsin C Mutations Causing Phenotypical Papillion Lafevre/Haim‐Munk Syndrome: A Case Report and Review of WES Findings
8天前
已完结
Enzymatic, structural, and biophysical characterization of a single‐domain antibody (VHH) selectively and tightly inhibiting neutrophil elastase and exhibiting favorable developability properties
10天前
已完结
Bioactive Proteinase 3 on the Cell Surface of Human Neutrophils: Quantification, Catalytic Activity, and Susceptibility to Inhibition
13天前
已完结
皖公网安备34019202002308
